Vaxcyte (PCVX) Competitors

$51.06 +0.04 (+0.08%)

Closing price 04:00 PM Eastern

Extended Trading

$51.44 +0.38 (+0.75%)

As of 05:08 PM Eastern

PCVX vs. BNTX, INSM, ROIV, VTRS, and MRNA

Should you buy Vaxcyte stock or one of its competitors? MarketBeat compares Vaxcyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxcyte include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Vaxcyte compare to BioNTech?

Vaxcyte (NASDAQ:PCVX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 68.43%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 38.66%. Given Vaxcyte's higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
BioNTech	-44.39%	-5.30%	-4.62%

Vaxcyte has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
BioNTech	$3.25B	7.28	-$1.29B	-$5.88	N/A

In the previous week, BioNTech had 5 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for BioNTech and 3 mentions for Vaxcyte. BioNTech's average media sentiment score of 0.72 beat Vaxcyte's score of 0.47 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Insmed?

Vaxcyte (NASDAQ:PCVX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Insmed	-144.44%	-130.11%	-51.57%

Vaxcyte has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Insmed	$819.56M	28.66	-$1.28B	-$5.75	N/A

96.8% of Vaxcyte shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Insmed had 12 more articles in the media than Vaxcyte. MarketBeat recorded 15 mentions for Insmed and 3 mentions for Vaxcyte. Insmed's average media sentiment score of 1.19 beat Vaxcyte's score of 0.47 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 68.43%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 94.66%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Vaxcyte and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

In the previous week, Roivant Sciences had 7 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Roivant Sciences and 3 mentions for Vaxcyte. Roivant Sciences' average media sentiment score of 0.63 beat Vaxcyte's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,589.00	-$299.77M	-$0.60	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential upside of 12.42%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 68.43%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Vaxcyte	N/A	-32.51%	-29.51%

Summary

Roivant Sciences beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Viatris?

Vaxcyte (NASDAQ:PCVX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Vaxcyte and Vaxcyte both had 3 articles in the media. Viatris' average media sentiment score of 0.93 beat Vaxcyte's score of 0.47 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 68.43%. Viatris has a consensus target price of $16.43, suggesting a potential upside of 1.98%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Vaxcyte has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A

Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Viatris	-2.04%	19.04%	7.62%

Summary

Vaxcyte beats Viatris on 9 of the 14 factors compared between the two stocks.

How does Vaxcyte compare to Moderna?

Vaxcyte (NASDAQ:PCVX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Moderna	-143.55%	-26.64%	-19.32%

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 68.43%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 24.88%. Given Vaxcyte's stronger consensus rating and higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 7 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Moderna and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.47 beat Moderna's score of -0.01 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has higher earnings, but lower revenue than Moderna. Vaxcyte is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Moderna	$1.94B	9.71	-$2.82B	-$8.15	N/A

Summary

Vaxcyte beats Moderna on 9 of the 15 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.37B	$3.40B	$6.44B	$12.57B
Dividend Yield	N/A	2.27%	2.75%	5.25%
P/E Ratio	-7.42	18.98	21.55	26.15
Price / Sales	N/A	344.00	618.79	118.16
Price / Cash	N/A	122.89	43.13	56.80
Price / Book	2.46	7.16	10.53	7.26
Net Income	-$766.63M	$24.20M	$3.56B	$337.24M
7 Day Performance	7.74%	3.98%	3.20%	3.91%
1 Month Performance	-13.06%	6.00%	4.59%	5.84%
1 Year Performance	62.72%	66.46%	37.81%	38.37%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.9123 of 5 stars	$51.06 +0.1%	$86.00 +68.4%	+60.8%	$7.37B	N/A	N/A	160
BNTX BioNTech	3.3181 of 5 stars	$92.14 flat	$128.44 +39.4%	-5.6%	$23.30B	$3.25B	N/A	7,807	Analyst Upgrade
INSM Insmed	3.7965 of 5 stars	$106.24 flat	$210.95 +98.6%	+56.4%	$23.03B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	2.898 of 5 stars	$29.96 flat	$33.05 +10.3%	+174.9%	$21.44B	$8.26M	N/A	860	Analyst Forecast
VTRS Viatris	2.9327 of 5 stars	$16.65 flat	$16.43 -1.3%	+89.4%	$19.39B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors